Service Communautaire d'Information sur la Recherche et le Développement - CORDIS

FP6

LUNAMICE Résumé de rapport

Project ID: 39241
Financé au titre de: FP6-MOBILITY
Pays: Spain

Final Activity and Management Report Summary - LUNAMICE (Soy-peptide Lunasin as potential colon cancer preventive agent)

Lunasin is a peptide identified in soybean and other seeds and plants by Prof. de Lumen in 1997. This peptide has demonstrated to exert chempopreventive properties by in vitro and in vivo assays. During my stay at the University of California, Berkeley, I conducted different studies focused on evaluating these properties against breast cancer as well as on elucidating lunasin's mechanism of action. We have demonstrated that lunasin inhibits cell proliferation, arrests cell cycle and induces apoptosis in human breast cancer MDA-MB-231 cells. Lunasin seems to modulate expression of different genes and proteins involved in cell cycle, apoptosis and signalling transduction in these cells. Moreover, an epigenetic mechanism of action has been revealed. Lunasin acts inhibiting histones H3 and H4 acetylation. This peptide has also been found to inhibit cell growth of fibroblast cells induced by chemical carcinogens.

An interesting result from the studies conducted at Prof. de Lumens' group has been founding that lunasin potentates aspirin's effects against breast cancer. Combination lunasin/aspirin is shown as a promising strategy against mamary tumour, although new experiments with animal models and human trials should be needed to confirm these results. In summary, lunasin is becoming an important peptide with promising cancer preventive properties. In addition to those effects desmonstrated during my stay at UC Berkeley, different international groups have reported lunasin's effects against colon cancer and leukaemia, opening a new door for future studies focused on determining these effects against other types of cancer.

Contact

Isidra RECIO SÃNCHEZ
Tél.: +34-9156-22900
Fax: +34-9156-44853
E-mail